Lessons From Bluebird Bio: How To Launch Advanced Therapies in Germany
Outcomes-based deals are important for launching cell and gene therapies in Germany, but bluebird bio’s painful experience with Zynteglo shows the importance of the taking the right approach to ensure market success.
You may also be interested in...
Bluebird bio’s decision to focus on the US market is being seen as a broader signal of the need for changes in market access policies to enable gene therapies to be made available for European patients. Only collaborative work will create solutions acceptable to payers and companies, and finding an acceptable price that both can live with will be crucial.
The head of Novartis Gene Therapies in Europe tells Scrip that innovative payment models and involving all stakeholders have helped payers see beyond a simple price tag and see the benefits of a one-time gene therapy for spinal muscular atrophy.
Two orphan drugs, Chiesi’s Proscybi and Insmed’s Arikayce, were rejected for funding on the Scottish National Health Service.